NCT06706596 A Systemic Screening for TB Disease in High-risk Groups in Barcelona
| NCT ID | NCT06706596 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Fundació Institut Germans Trias i Pujol |
| Condition | Tuberculosis |
| Study Type | OBSERVATIONAL |
| Enrollment | 3,000 participants |
| Start Date | 2022-07-22 |
| Primary Completion | 2026-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 3,000 participants in total. It began in 2022-07-22 with a primary completion date of 2026-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this screening study is to identify and screen vulnerable population in Barcelona for active pulmonary tuberculosis
Eligibility Criteria
Inclusion Criteria: -Belonging to a population at high risk for tuberculosis (TB) Exclusion Criteria: -Not belonging to a population at high risk for tuberculosis (TB)
Contact & Investigator
Cristina Vilaplana, MD, PhD
STUDY CHAIR
Fundació i Hospital Germans Trias i Pujol (IGTP-HUGTIP)
Frequently Asked Questions
Who can join the NCT06706596 clinical trial?
This trial is open to participants of all sexes, studying Tuberculosis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06706596 currently recruiting?
Yes, NCT06706596 is actively recruiting participants. Contact the research team at cvilaplana@igtp.cat for enrollment information.
Where is the NCT06706596 trial being conducted?
This trial is being conducted at Badalona, Spain.
Who is sponsoring the NCT06706596 clinical trial?
NCT06706596 is sponsored by Fundació Institut Germans Trias i Pujol. The principal investigator is Cristina Vilaplana, MD, PhD at Fundació i Hospital Germans Trias i Pujol (IGTP-HUGTIP). The trial plans to enroll 3,000 participants.